MATERIAL DEPOSITING SYSTEM FOR TREATING A PATIENT

1 . (canceled)

2 . A method of treating a medical condition of a patient, comprising:

selecting a patient;

harvesting tissue from a harvest site a mammalian subject via a harvesting device; and

depositing material at a deposit site in the patient via a depositing device, the material being based on the harvested tissue;

wherein the deposited material is configured to generate resultant tissue configured to treat the medical condition of the patient,

wherein the medical condition treated comprises Type 2 diabetes.

3 . The method according to claim 2 , wherein the medical condition treated further comprises a medical condition selected from the group consisting of: Type 1 diabetes; double diabetes; gestational diabetes; hyperglycemia; pre-diabetes; monogenic diabetes; maturity onset diabetes of the young; impaired glucose tolerance; insulin resistance; hyperinsulinemia; hypoinsulinemia; non-diabetic hypoglycemia; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; obesity; obesity-related disorder; polycystic ovarian syndrome; hypertriglyceridemia; hypercholesterolemia; psoriasis; Alzheimer's disease; and combinations thereof.

4 . The method according to claim 2 , wherein the harvest site comprises an anatomical location selected from the group consisting of: the gastrointestinal tract; the mouth; the esophagus; the stomach; the duodenum; the jejunum; the ileum; the colon; an organ; the brain; the lungs; the liver; the bladder; the kidneys; the heart; the small intestine; the large intestine; the skin; the peritoneal cavity; and combinations thereof.

5 . The method according to claim 2 , wherein the harvest site comprises one or more locations in the ileum and/or colon.

6 . The method according to claim 2 , wherein the harvested tissue comprises tissue selected from the group consisting of: mucosal tissue; submucosal tissue; tissue comprising at least one stem cell; tissue comprising at least one stem cell of the mucosa; tissue comprising at least one mucosal crypt containing a stem cell; mucosal tissue comprising at least one stem-cell containing crypt; organoids; epithelial layer tissue; uroepithelial layer tissue; intestinal epithelial layer tissue; lung epithelial layer tissue; and combinations thereof.

7 . The method according to claim 2 , wherein the deposit site comprises an anatomical location selected from the group consisting of: the gastrointestinal tract; the mouth; the esophagus; the stomach; the duodenum; the jejunum; the ileum; the colon; an organ; the brain; the lungs; the liver; the bladder; the kidneys; the heart; the small intestine; the large intestine; the skin; the peritoneal cavity; and combinations thereof.

8 . The method according to claim 2 , wherein the deposit site comprises one or more locations in the duodenum and/or proximal jejunum.

9 . The method according to claim 2 , wherein the deposit site comprises an anatomical location selected from the group consisting of: luminal wall tissue of the gastrointestinal tract; mucosal tissue of the gastrointestinal tract; submucosal tissue of the gastrointestinal tract; the peritoneal cavity; and combinations thereof.

10 . The method according to claim 2 , further comprising processing the harvested tissue prior to deposition in the patient.

11 . The method according to claim 10 , wherein the harvested tissue is amplified.

12 . The method according to claim 10 , wherein the harvested tissue is transgenically modified.

13 . The method according to claim 2 , wherein the depositing of the material is configured to modify neurohormonal signaling in the gastrointestinal tract.

14 . The method according to claim 2 , wherein the depositing device comprises at least two depositing elements configured to deposit the material at the deposit site.

15 . The method according to claim 2 , wherein the material further comprises a protecting element configured to protect the material after depositing of the material at the deposit site.

16 . The method according to claim 2 , further comprising treating tissue proximate the deposit site via a treatment device prior to depositing the material.

17 . The method according to claim 16 , wherein the treatment device comprises a tissue ablation device configured to ablate tissue proximate the deposit site.

18 . The method according to claim 17 , wherein the tissue ablation device is configured to ablate mucosal tissue proximate the deposit site.

19 . The method according to claim 16 , wherein the treatment device comprises a tissue expansion device configured to expand tissue proximate the deposit site.

20 . The method according to claim 2 , wherein the patient is selected to have a minimum level of pancreatic functionality.

21 . The method according to claim 20 , wherein the minimum level of pancreatic functionality is based on the patient's c-peptide level.